Targeting Adjuvant Chemotherapy: A Good Idea That Needs to Be Proven!
Cet article analyse la controverse sur les tests permettant de prédire la réponse à une chimiothérapie adjuvante dans le cancer du sein
The success of adjuvant therapy in reducing recurrence and mortality has been established for endocrine therapy, chemotherapy, and more recently, trastuzumab. Indeed, Berry et al. have suggested that at least one half of the remarkable reduction in breast cancer mortality observed over the last 30 years can be attributed to widespread application of adjuvant systemic therapy. The Oxford Worldwide Overview of early breast cancer trials, conducted by the Early Breast Cancer Trialists Collaborative Group (EBCTG) demonstrated definitively that, without respect to subgrouping, chemotherapy appears to reduce breast cancer recurrence and mortality by approximately 30% and 20%, respectively. (...]
Journal of Clinical Oncology , article en libre accès, 2012